BioSpace News Archive

C2N Diagnostics continues to build on its mission to provide exceptional laboratory services and products in the field of brain health.

Aravive, Inc. announced that the company’s Chairman, Fred Eshelman, Pharm.D., through Eshelman Ventures, LLC, agreed to purchase a pre-funded warrant to purchase 4,545,455 shares of the company’s common stock at a price of $2.20 per share, which was the consolidated closing bid price of the company’s common stock on The Nasdaq Global Select Market on December 31, 2021.

Asieris Pharmaceuticals (Asieris), today announced that the world’s first patient dose has been administered in U.S. for its oral APL-1202 in combination with BeiGene’s tislelizumab as neoadjuvant therapy in patients with muscle invasive bladder cancer (MIBC).

On December 30th, 2021, Belief BioMed Group (BBM) announced that it has successfully dosed the first subject in the registrational gene therapy clinical trial by intravenous (IV) infusion of BBM-H901, an adeno-associated virus (AAV) vector expressing factor IX gene for treatment of adult male hemophilia B patients.

Joint research results from Biologics of Jemincare and Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences (CAS) confirmed that JMB2002, an anti-SARS-CoV-2 neutralizing antibody (NAb) discovered by Biologics of Jemincare is still effective against Omicron variant of SARS-CoV-2.

Press release - Oslo, Norway, 3 January 2022: Photocure ASA announces the start of its Cysview® sales, marketing and distribution operations in the Canadian market.

Ryvu Therapeutics announced that it will participate in the following upcoming virtual investor conferences

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Ms. Judith Robertson as the Company’s first Chief Commercial Officer, effective 1 January 2022.

Bionomics Limited, a clinical-stage biopharmaceutical company, is pleased to announce that it has initiated its Phase 2 clinical trial to evaluate BNC210 for the acute treatment of Social Anxiety Disorder, with topline results expected by the end of 2022.

Exact Sciences Corp. announced that company management will participate in the following virtual conference and invited investors to participate by webcast.